{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:28:04Z","timestamp":1791217684614,"version":"4.1.0"},"reference-count":242,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,5,28]],"date-time":"2013-05-28T00:00:00Z","timestamp":1369699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CA A Cancer J Clinicians"],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:p>\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.wileyhealthlearning.com\/acs.aspx\">Answer questions and earn CME\/CNE<\/jats:ext-link>\n                  <\/jats:p>\n                  <jats:p>\n                    Advances in genomics and molecular biology have identified aberrant proteins in cancer cells that are attractive targets for cancer therapy. Because these proteins are overexpressed or dysregulated in cancer cells compared with normal cells, it was assumed that their inhibitors will be narrowly targeted and relatively nontoxic. However, this hope has not been achieved. Current targeted agents exhibit the same frequency and severity of toxicities as traditional cytotoxic agents, with the main difference being the nature of the toxic effects. Thus, the classical chemotherapy toxicities of alopecia, myelosuppression, mucositis, nausea, and vomiting have been generally replaced by vascular, dermatologic, endocrine, coagulation, immunologic, ocular, and pulmonary toxicities. These toxicities need to be recognized, prevented, and optimally managed.\n                    <jats:bold>CA Cancer J Clin 2013;63:249\u2013279.<\/jats:bold>\n                    <jats:sup>\u00a9<\/jats:sup>\n                    <jats:bold>2013 American Cancer Society, Inc.<\/jats:bold>\n                  <\/jats:p>","DOI":"10.3322\/caac.21184","type":"journal-article","created":{"date-parts":[[2013,5,28]],"date-time":"2013-05-28T16:49:09Z","timestamp":1369759749000},"page":"249-279","source":"Crossref","is-referenced-by-count":238,"title":["Understanding, recognizing, and managing toxicities of targeted anticancer therapies"],"prefix":"10.3322","volume":"63","author":[{"given":"Grace K.","family":"Dy","sequence":"first","affiliation":[{"name":"Department of Medicine Roswell Park Cancer Institute Buffalo New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex A.","family":"Adjei","sequence":"additional","affiliation":[{"name":"Department of Medicine Roswell Park Cancer Institute Buffalo New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,5,28]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.3824"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1995.tb00206.x"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.10.010"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0082"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25090"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000229751"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2011.04117.x"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-011-1197-6"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq387"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.7828"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.6987"},{"key":"e_1_2_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.03.046"},{"key":"e_1_2_4_14_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0365"},{"key":"e_1_2_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.10.004"},{"key":"e_1_2_4_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1451-6"},{"key":"e_1_2_4_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.4823"},{"key":"e_1_2_4_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"e_1_2_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60398-5"},{"key":"e_1_2_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60868-X"},{"key":"e_1_2_4_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002011"},{"key":"e_1_2_4_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08902"},{"key":"e_1_2_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.12.040"},{"key":"e_1_2_4_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105358"},{"key":"e_1_2_4_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.7680"},{"key":"e_1_2_4_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/107327480901600110"},{"key":"e_1_2_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70269-3"},{"key":"e_1_2_4_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203421"},{"key":"e_1_2_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70270-X"},{"key":"e_1_2_4_30_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.8510","article-title":"Updated safety and efficacy results from a phase I\/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1\/2 inhibitor trametinib (GSK1120212) in patients with BRAFi\u2010naive metastatic melanoma [Abstract]","volume":"30","author":"Weber KS","year":"2012","journal-title":"J Clin Oncol."},{"key":"e_1_2_4_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1114329"},{"key":"e_1_2_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(11)72324-3"},{"issue":"11","key":"e_1_2_4_33_1","article-title":"First\u2010in\u2010patient study of PF\u201004691502, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on safety, efficacy, and pharmacology [Abstract]","volume":"10","author":"Millham R","year":"2011","journal-title":"Mol Cancer Ther."},{"key":"e_1_2_4_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-009-0127-8"},{"key":"e_1_2_4_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2010.07449_supp.x"},{"key":"e_1_2_4_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08357.x"},{"key":"e_1_2_4_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn389"},{"key":"e_1_2_4_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi204"},{"key":"e_1_2_4_39_1","first-page":"2307","article-title":"The pathogenetic mechanism of anthracycline\u2010induced palmar\u2010plantar erythrodysesthesia","volume":"29","author":"Martschick A","year":"2009","journal-title":"Anticancer Res."},{"key":"e_1_2_4_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/anatox\/35.8.558"},{"key":"e_1_2_4_41_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.30.1.52"},{"key":"e_1_2_4_42_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.e13591","article-title":"Bevacizumab and risk of hand\u2010foot syndrome associated with chemotherapy [Abstract]","volume":"30","author":"Flores RA","year":"2012","journal-title":"J Clin Oncol."},{"key":"e_1_2_4_43_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1141"},{"key":"e_1_2_4_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.0108"},{"key":"e_1_2_4_45_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.052530"},{"key":"e_1_2_4_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.1538"},{"key":"e_1_2_4_47_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1766"},{"key":"e_1_2_4_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/34681"},{"key":"e_1_2_4_49_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5070\/D3472203P2","article-title":"Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST","volume":"14","author":"Alexandrescu DT","year":"2008","journal-title":"Dermatol Online J."},{"key":"e_1_2_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.06.029"},{"key":"e_1_2_4_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200208083470614"},{"key":"e_1_2_4_52_1","first-page":"1062","article-title":"Pigmentary changes in a patient treated with imatinib","volume":"10","author":"Balagula Y","year":"2011","journal-title":"J Drugs Dermatol."},{"key":"e_1_2_4_53_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.177"},{"key":"e_1_2_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(98)70443-9"},{"key":"e_1_2_4_55_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI11317"},{"key":"e_1_2_4_56_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.122249299"},{"key":"e_1_2_4_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0502-459"},{"key":"e_1_2_4_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1215"},{"key":"e_1_2_4_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9663-z"},{"key":"e_1_2_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2010.09.001"},{"key":"e_1_2_4_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr294"},{"key":"e_1_2_4_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)60896-3"},{"key":"e_1_2_4_63_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0701286104"},{"key":"e_1_2_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2010.11.002"},{"key":"e_1_2_4_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1446"},{"key":"e_1_2_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61865-0"},{"key":"e_1_2_4_67_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.091415198"},{"key":"e_1_2_4_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1752-8062.2008.00090.x"},{"key":"e_1_2_4_69_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32373"},{"key":"e_1_2_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.01.004"},{"key":"e_1_2_4_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12012-009-9056-0"},{"key":"e_1_2_4_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2010.08.026"},{"key":"e_1_2_4_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2009.12.032"},{"key":"e_1_2_4_74_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvq217"},{"key":"e_1_2_4_75_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfn157"},{"key":"e_1_2_4_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfs192"},{"key":"e_1_2_4_77_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.86.6.692"},{"key":"e_1_2_4_78_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI10226"},{"key":"e_1_2_4_79_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.109.211276"},{"key":"e_1_2_4_80_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.6.660"},{"issue":"15","key":"e_1_2_4_81_1","article-title":"Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non\u2010small cell lung cancer (NSCLC) [Abstract]","volume":"28","author":"Jassem J","year":"2010","journal-title":"J Clin Oncol."},{"key":"e_1_2_4_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.94"},{"key":"e_1_2_4_83_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707330"},{"key":"e_1_2_4_84_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.1759"},{"key":"e_1_2_4_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2003.12.061"},{"key":"e_1_2_4_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402866"},{"key":"e_1_2_4_87_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.e18140","article-title":"Should crizotinib be dosed to sinus bradycardia (SB) (HR\u2009<\u200955)? A single institution, retrospective analysis of heart rate (HR) changes and tumor response in crizotinib treated NSCLC patients [Abstract]","volume":"30","author":"Tong W","year":"2012","journal-title":"J Clin Oncol."},{"key":"e_1_2_4_88_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.6925"},{"key":"e_1_2_4_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjp.2008.203"},{"key":"e_1_2_4_90_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djm086"},{"key":"e_1_2_4_91_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.2757"},{"key":"e_1_2_4_92_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03212.x"},{"key":"e_1_2_4_93_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0988-x"},{"key":"e_1_2_4_94_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.51"},{"key":"e_1_2_4_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70222-0"},{"key":"e_1_2_4_96_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22037"},{"key":"e_1_2_4_97_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr292"},{"key":"e_1_2_4_98_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.6844"},{"key":"e_1_2_4_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405062"},{"key":"e_1_2_4_100_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.1283"},{"key":"e_1_2_4_101_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-344333"},{"key":"e_1_2_4_102_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.656"},{"key":"e_1_2_4_103_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr592"},{"key":"e_1_2_4_104_1","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/305234"},{"key":"e_1_2_4_105_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds115"},{"key":"e_1_2_4_106_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.2235"},{"key":"e_1_2_4_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.03.012"},{"key":"e_1_2_4_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-5231(03)00143-6"},{"key":"e_1_2_4_109_1","article-title":"Phase I study of intravenous PI3K inhibitor BAY 80\u20106946: Activity in patients (pts) with advanced solid tumors and non\u2010Hodgkin lymphoma treated in MTD expansion cohorts [Abstract]","volume":"30","author":"Lotzke MT","year":"2012","journal-title":"J Clin Oncol."},{"key":"e_1_2_4_110_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.3020","article-title":"A first\u2010in\u2010human phase I study to evaluate GDC\u20100980, an oral PI3K\/mTOR inhibitor, administered QD in patients with advanced solid tumors [Abstract]","volume":"29","author":"Wagner AJ","year":"2011","journal-title":"J Clin Oncol."},{"key":"e_1_2_4_111_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hys005"},{"key":"e_1_2_4_112_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200710-1501OC"},{"key":"e_1_2_4_113_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2008.00857.x"},{"key":"e_1_2_4_114_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201002-0188OC"},{"key":"e_1_2_4_115_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-011-0921-9"},{"key":"e_1_2_4_116_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9260"},{"key":"e_1_2_4_117_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.032"},{"key":"e_1_2_4_118_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390120"},{"key":"e_1_2_4_119_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.079921"},{"key":"e_1_2_4_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.03.010"},{"key":"e_1_2_4_121_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr373"},{"key":"e_1_2_4_122_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1172"},{"key":"e_1_2_4_123_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2507"},{"key":"e_1_2_4_124_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2822"},{"key":"e_1_2_4_125_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1837"},{"key":"e_1_2_4_126_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-0586"},{"key":"e_1_2_4_127_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2324"},{"key":"e_1_2_4_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2011.04.014"},{"key":"e_1_2_4_129_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.070719"},{"key":"e_1_2_4_130_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.9730"},{"key":"e_1_2_4_131_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030604"},{"key":"e_1_2_4_132_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr010"},{"key":"e_1_2_4_133_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr525"},{"key":"e_1_2_4_134_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e32833760bf"},{"key":"e_1_2_4_135_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq172"},{"key":"e_1_2_4_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2004.07.013"},{"key":"e_1_2_4_137_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0b013e3283546ee0"},{"key":"e_1_2_4_138_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.114"},{"key":"e_1_2_4_139_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.183"},{"key":"e_1_2_4_140_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27450"},{"key":"e_1_2_4_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2004.11.003"},{"key":"e_1_2_4_142_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2011.495"},{"key":"e_1_2_4_143_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.109.189506"},{"key":"e_1_2_4_144_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07329.x"},{"key":"e_1_2_4_145_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810246105"},{"key":"e_1_2_4_146_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2012.02.027"},{"key":"e_1_2_4_147_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-2980.2009.00393.x"},{"key":"e_1_2_4_148_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70108-0"},{"key":"e_1_2_4_149_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31680"},{"key":"e_1_2_4_150_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008030327"},{"key":"e_1_2_4_151_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2009111153"},{"key":"e_1_2_4_152_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.8511","article-title":"Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations [Abstract]","volume":"30","author":"Ascierto PA","year":"2012","journal-title":"J Clin Oncol."},{"key":"e_1_2_4_153_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0742"},{"key":"e_1_2_4_154_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0868"},{"key":"e_1_2_4_155_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-012-0204-1"},{"key":"e_1_2_4_156_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11680"},{"key":"e_1_2_4_157_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605366"},{"key":"e_1_2_4_158_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djm328"},{"key":"e_1_2_4_159_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0405225"},{"key":"e_1_2_4_160_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2010.04.005"},{"key":"e_1_2_4_161_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2332"},{"key":"e_1_2_4_162_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2516"},{"key":"e_1_2_4_163_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210757"},{"key":"e_1_2_4_164_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_2_4_165_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3706"},{"key":"e_1_2_4_166_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1002"},{"key":"e_1_2_4_167_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70344-3"},{"key":"e_1_2_4_168_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27575"},{"key":"e_1_2_4_169_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-318055"},{"key":"e_1_2_4_170_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2007.06.015"},{"key":"e_1_2_4_171_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.31.305"},{"key":"e_1_2_4_172_1","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2010.136"},{"key":"e_1_2_4_173_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.262"},{"key":"e_1_2_4_174_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1173"},{"key":"e_1_2_4_175_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.01.037"},{"key":"e_1_2_4_176_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-344812"},{"key":"e_1_2_4_177_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11863"},{"key":"e_1_2_4_178_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24432"},{"key":"e_1_2_4_179_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.11.001"},{"key":"e_1_2_4_180_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.3007","article-title":"Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86\u20109766 (RDEA119), a MEK inhibitor, in patients with advanced cancer [Abstract]","volume":"29","author":"Gore L","year":"2011","journal-title":"J Clin Oncol."},{"key":"e_1_2_4_181_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1883"},{"key":"e_1_2_4_182_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.1360"},{"issue":"15","key":"e_1_2_4_183_1","article-title":"First\u2010in\u2010human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK\u2010inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors [Abstract]","volume":"28","author":"Delord J","year":"2010","journal-title":"J Clin Oncol."},{"issue":"15","key":"e_1_2_4_184_1","article-title":"Phase I dose\u2010escalation study of E6201, a MEK\u20101 inhibitor, in advanced solid tumors [Abstract]","volume":"28","author":"Borad MJ","year":"2010","journal-title":"J Clin Oncol."},{"key":"e_1_2_4_185_1","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2010.131"},{"key":"e_1_2_4_186_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.05.047"},{"key":"e_1_2_4_187_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2009.10.019"},{"key":"e_1_2_4_188_1","doi-asserted-by":"publisher","DOI":"10.1159\/000185557"},{"key":"e_1_2_4_189_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300830"},{"key":"e_1_2_4_190_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(00)00035-0"},{"key":"e_1_2_4_191_1","doi-asserted-by":"publisher","DOI":"10.1159\/000322145"},{"key":"e_1_2_4_192_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.128"},{"key":"e_1_2_4_193_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1950"},{"key":"e_1_2_4_194_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70081-X"},{"key":"e_1_2_4_195_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-294983"},{"key":"e_1_2_4_196_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2012.04.001"},{"key":"e_1_2_4_197_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-403733"},{"key":"e_1_2_4_198_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.8282"},{"key":"e_1_2_4_199_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.1540"},{"key":"e_1_2_4_200_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03659"},{"key":"e_1_2_4_201_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03911.x"},{"key":"e_1_2_4_202_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2484"},{"key":"e_1_2_4_203_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605653"},{"key":"e_1_2_4_204_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404827"},{"key":"e_1_2_4_205_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2006.04061.x"},{"key":"e_1_2_4_206_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.18-04-01337.1998"},{"key":"e_1_2_4_207_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2009.0060"},{"key":"e_1_2_4_208_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.2501","article-title":"Progression\u2010free survival (PFS) from a phase I study of crizotinib (PF\u201002341066) in patients with ALK\u2010positive non\u2010small cell lung cancer (NSCLC) [Abstract]","volume":"29","author":"Camidge DR","year":"2011","journal-title":"J Clin Oncol."},{"key":"e_1_2_4_209_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.10.026"},{"issue":"15","key":"e_1_2_4_210_1","article-title":"AUY922, a novel HSP90 inhibitor: Final results of a first\u2010in\u2010human study in patients with advanced solid malignancies [Abstract]","volume":"28","author":"Samuel TA","year":"2010","journal-title":"J Clin Oncol."},{"key":"e_1_2_4_211_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.3086","article-title":"Associating retinal drug exposure and retention with the ocular toxicity profiles of Hsp90 inhibit [Abstract]","volume":"30","author":"Zhou D","year":"2012","journal-title":"J Clin Oncol."},{"key":"e_1_2_4_212_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr511"},{"key":"e_1_2_4_213_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-010-0127-z"},{"key":"e_1_2_4_214_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0153"},{"key":"e_1_2_4_215_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.144"},{"key":"e_1_2_4_216_1","doi-asserted-by":"publisher","DOI":"10.1586\/ern.12.5"},{"key":"e_1_2_4_217_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9641"},{"key":"e_1_2_4_218_1","unstructured":"FDA\u2010approved prescription drug labeling for Velcade (bortezomib).accessdata.fda. gov\/drugsatfda_docs\/label\/2012\/021602 s027lbl.pdf. Accessed October 21 2012."},{"key":"e_1_2_4_219_1","unstructured":"FDA\u2010approved prescription drug labeling for Jakafi (ruxolitinib).accessdata.fda. gov\/drugsatfda_docs\/label\/2011\/202192l bl.pdf. Accessed October 19 2012."},{"key":"e_1_2_4_220_1","unstructured":"FDA\u2010approved prescription drug labeling for Revlimid (lenalidomide).accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/0218 80s028lbl.pdf. Accessed October 21 2012."},{"key":"e_1_2_4_221_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2004.09.003"},{"key":"e_1_2_4_222_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P044"},{"key":"e_1_2_4_223_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.048496"},{"key":"e_1_2_4_224_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.254"},{"key":"e_1_2_4_225_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-439158"},{"key":"e_1_2_4_226_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-373514"},{"key":"e_1_2_4_227_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa074943"},{"key":"e_1_2_4_228_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.7812"},{"key":"e_1_2_4_229_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1468"},{"key":"e_1_2_4_230_1","doi-asserted-by":"publisher","DOI":"10.1080\/02841860802609574"},{"key":"e_1_2_4_231_1","doi-asserted-by":"publisher","DOI":"10.1080\/02841860902974167"},{"key":"e_1_2_4_232_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318257fc1d"},{"key":"e_1_2_4_233_1","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2011.0518"},{"key":"e_1_2_4_234_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042875"},{"key":"e_1_2_4_235_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.7679"},{"key":"e_1_2_4_236_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31824166c1"},{"key":"e_1_2_4_237_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1315"},{"key":"e_1_2_4_238_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2381"},{"key":"e_1_2_4_239_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26429"},{"key":"e_1_2_4_240_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2436"},{"key":"e_1_2_4_241_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003377"},{"key":"e_1_2_4_242_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2012.08.005"},{"key":"e_1_2_4_243_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2010.04.006"}],"container-title":["CA: A Cancer Journal for Clinicians"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.3322%2Fcaac.21184","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.3322\/caac.21184","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T13:25:46Z","timestamp":1762349146000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.3322\/caac.21184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,28]]},"references-count":242,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.3322\/caac.21184"],"URL":"https:\/\/doi.org\/10.3322\/caac.21184","archive":["Portico"],"relation":{},"ISSN":["0007-9235","1542-4863"],"issn-type":[{"value":"0007-9235","type":"print"},{"value":"1542-4863","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,28]]}}}